Company intelligence / Profile preview
Empath Biosciences
- Ownership
- Private
- Development stage
- Preclinical
Overview
Empath Biosciences is developing a proprietary drug discovery platform that leverages biodiversity from novel or understudied bacteria to identify new small molecule therapeutics. Their lead program targets F1-ATPase with glycomacrolide compounds derived from natural products. The lead asset is in IND-enabling studies with plans to enter clinical trials in 2026. The company claims its approach can triple optimized leads and improve technical/regulatory success rates over standard small-molecule discovery methods by >50%. No published clinical results yet.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (natural product-derived and engineered)Glycomacrolides (novel chemical class from natural products)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Empath Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Empath Biosciences.